Kura Oncology, Inc.

How big is Kura Oncology, Inc.?

As of Jun 18, Kura Oncology, Inc. has a market capitalization of 536.76 million and reported net sales of 67.99 million with a net profit of -181.89 million over the latest four quarters.

As of Jun 18, Kura Oncology, Inc. has a market capitalization of 536.76 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 67.99 million, while the sum of net profit for the same period is -181.89 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 413.64 million, and the total assets amount to 1,040.67 million.

What does Kura Oncology, Inc. do?

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized therapies for solid tumors and blood cancers. As of March 2025, it reported net sales of $14 million and a net loss of $57 million, with a market cap of $536.76 million.

Overview:<BR>Kura Oncology, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 14 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -57 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 536.76 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.77 <BR>Return on Equity: -49.91% <BR>Price to Book: 1.47<BR><BR>Contact Details:<BR>Address: 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA: 92130 <BR>Tel: 1 858 5008800 <BR>Fax: 1 302 6555049 <BR>Website: https://www.kuraoncology.com/

Should I buy, sell or hold Kura Oncology, Inc.?

Who are in the management team of Kura Oncology, Inc.?

As of March 2022, Kura Oncology's management team includes Dr. Troy Wilson as Chairman, President, and CEO, with Mr. Faheem Hasnain as Lead Independent Director and independent directors Mr. Robert Hoffman, Mr. Thomas Malley, Ms. Diane Parks, and Dr. Steven Stein.

As of March 2022, the management team of Kura Oncology, Inc. includes Dr. Troy Wilson, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Faheem Hasnain as the Lead Independent Director, along with independent directors Mr. Robert Hoffman, Mr. Thomas Malley, Ms. Diane Parks, and Dr. Steven Stein.

Is Kura Oncology, Inc. overvalued or undervalued?

As of February 26, 2025, Kura Oncology, Inc. is considered overvalued with a "risky" valuation grade due to concerning financial metrics, including a Price to Book Value of 1.60, a negative ROE of -49.91%, and an EV to EBITDA ratio significantly lower than the industry average, indicating inefficiencies in generating returns and insufficient earnings relative to its enterprise value.

As of 26 February 2025, Kura Oncology, Inc. has moved from a "does not qualify" to a "risky" valuation grade. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.60 and an EV to EBITDA ratio of 0.32, which suggests that the market may be pricing in future growth that is not currently supported by earnings. Additionally, the company's ROCE stands at a high 72.06%, but this is contrasted by a negative ROE of -49.91%, indicating inefficiencies in generating returns for shareholders.<BR><BR>In comparison to its peers, Kura's valuation metrics are concerning; for instance, its EV to EBITDA of -0.3981 is significantly lower than the industry average, suggesting that it is not generating sufficient earnings relative to its enterprise value. The stock has not shown recent returns against the S&P 500, which further complicates the investment narrative. Overall, Kura Oncology, Inc. is currently overvalued based on its financial ratios and peer comparisons.

Is Kura Oncology, Inc. technically bullish or bearish?

As of October 3, 2025, Kura Oncology, Inc. shows a mildly bullish trend, supported by weekly indicators, despite bearish monthly signals and a significant 1-year underperformance of -45.68% compared to the S&P 500's 17.82%.

As of 3 October 2025, the technical trend for Kura Oncology, Inc. has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly MACD and KST are bearish. The daily moving averages are bullish, and Dow Theory shows a mildly bullish trend on both weekly and monthly time frames. The RSI shows no signal in both weekly and monthly periods. <BR><BR>In terms of performance, Kura has outperformed the S&P 500 over the past week and month, with returns of 9.25% and 19.22% respectively, but has significantly underperformed over the longer term, with a 1-year return of -45.68% compared to the S&P 500's 17.82%. Overall, the current technical stance is mildly bullish, driven primarily by the weekly indicators.